Business
Fulgent Genetics, Inc.: Moreover, we operate in a competitive and rapidly evolving industry, and new risks emerge from time to time.
Revenue increased 13.8% to $322.7M, while Net income decreased 41.7% to ($60.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $322.7MWatch
- Profitability — Net income ($60.5M)Watch
- Cash generation — Free cash flow ($124.2M)Note
- Accounting — Distress-safe · no manipulation flag · earnings quality safeOK
- Insiders — 0 buys; 13 sells in 365 daysNote
- Capital — share repurchases were $10.9MNote
Where the revenue comes from
Fiscal 2025, as Fulgent Genetics, Inc. reports it. History and quarterly detail are in the app.
- Laboratory Services$322.2M
- Therapeutic Development$447K
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Fulgent Genetics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.